Member Info for Moneymunch

‘Four FDA-approved drugs decrease overall mortality in humans’

Published on: September 6, 2024

Ahead of his appearance at Longevity Investors Conference, Nir Barzilai talks gerotherapeutics and choosing the right drugs for aging.

Take a unique mix of investors, scientists and entrepreneurs, a longevity-focused agenda packed with keynotes, panels and networking and put them in a glorious Swiss setting and you have the Longevity Investors Conference.

Kicking off later this month on 24th September in Gstaad, this year’s LIC boasts an extended agenda with numerous networking opportunities running over 2.5 days. LIC always boasts a stellar line-up of longevity key opinion leaders, and this means that program discusses the latest trends and developments, and connects investors with state-of-the-art scientific progress.

Nir Barzilai on…

Gerotherapeutics and the fantastic four

I want to highlight something new that happened to us without anybody noticing. A drug is gerotherapeutic if it has been shown to affect the hallmarks of aging, and the hallmarks of aging are all related – you might think you’re targeting metabolism, but you’re actually improving immunity as well. There are 12 drugs that affect the hallmarks of aging in animals preclinical studies, extending the healthspan and also the lifespan of the animals. But there are only four drugs that do this in humans. In humans, what we want to see in a clinical study is a drug that was designed for one indication, also affects other diseases or medical problems and finally, to see a drug that over a five year project is shown to decrease overall mortality – not disease specific mortality, but overall mortality.

..............

We’re looking for longevity genes in centenarians not only for the mechanism, but also from a drug development perspective. And in fact, my study has been used to develop two drugs. One is a CTP inhibitor by Merck and one is an ApoC-III inhibitor by Ionis as an example. So, this data is important and it connects straight to biotech. One of the things that we found is that some centenarians have mutation in SIRT6. SIRT6 is actually the sirtuin that when you target really extends healthspan and longevity in both sexes. You know, we were busy with SIRT1 and resveratrol, but it’s actually the SIRT6 that does it!

htTps://longevity.technology/news/four-fda-approved-drugs-decrease-overall-mortality-in-humans/

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,714 followers

3h

Last week's Annual Aging Research & Drug Discovery Meeting was a triumph! Investors and peers alike had the opportunity to learn more about Genflow Biosciences (LON:GENF) (OTCQB:GENFF) latest #SIRT6 research.

Learn more about #Genflow's innovative work: https://loom.ly/uh0pGy8

#aging #longevity #MASH #GENF #GENFF

You can read the majority Northeast if you click on the Linkden post and oom into the photograph of the poster. Gl ;-)))

"Human centenarian-associated Sirt6 mutants counteracts hepatic steatosis and fibrosis"

Conclusions

Sirt6, and more specifically Sirt6c, could reduce hepatic lipid accumulation and fibrotic phenotypes, such collagen secretion and deposition in HSC, as well as decrease stiffness in hepatocytes.

https://www.linkedin.com/posts/genflow-biosciences_sirt6-biotech-aging-activity-7234881247091589120-xdP9

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)’s Post

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,709 followers

3h

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s poster presentation at the 11th Annual Aging Research and Drug Discovery Meeting has been a standout success!

The company is showcasing its groundbreaking #SIRT6 research, which is sparking significant interest at the conference.

Stay tuned for more updates!

#biotech #aging #GENF #GENFF

Yes of course the 2 x 547.5k's must have been buys and even less shares in free float and can't wait for Eric to update the market on proceedings. Fingers crossed for a run of stellar newsflow to propel the sp to new highs in the coming weeks. Gl :-)

Fingers crossed Porter, looks like one for 547.5k went through yesterday, i phoned mine through a few months back after insisting i wanted to speak directly via the broker on my online trading account to make sure it was executed immediately. Looking forward to a Stellar September and beyond. Tick Tock ;-)

🧬 "Stay tuned for more updates"

Tick,Tock, can't be too much longer before take off, Excitement building!!! Gla holders :-)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,704 followers

2h

🎉 Kickoff Alert!

Today marks the start of the 11th Annual #Aging Research and Drug Discovery Meeting. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) CEO Dr. Eric Leire spoke about the company's lastest #SIRT6 research and discussed its implications on #MASH.

🧬 Stay tuned for more updates!

htTps://www.linkedin.com/posts/genflow-biosciences_aging-sirt6-mash-activity-7233801608856305664-fNrE

Cheers Porter, the sky is the limit, and so hopefully not to long before full market appreciation......Major pharma must be keeping an eye on proceedings and so very excited and extremely hopeful for a run of stellar news, including an update on Genflow's "upcoming " dog trials, which alone could be a company maker with an early Major JV partner doing their due diligence. Gl ;-)

Obesity Market inflection point.

What’s different in 2024 is that we are seeing the birth of a major new market for effective prescription medications which promise unprecedented impact not just on obesity, but on the health issues associated with obesity. The market is also seeing unprecedented willingness by patients to pay out of pocket, addressing the otherwise significant market access challenge, at least for wealthier patients, and creating new commercial opportunities, which will also be seen for the support of patients on their journey to weight reduction and better health. The rise of a new mega-sized therapy market for obesity agents could be a powerful contributory factor to the debut of the world’s first trillion-dollar value Life Sciences company, something which has not yet happened but in 2024 is moving to a real possibility.

htTps://www.iqvia.com/blogs/2024/02/2024-the-obesity-markets-inflection-point

Cheers Northeast, the comprehensive PubMed scholarly publication is by Genflow and their academic partners, highlighting the importance of Genflow's Sirt6 Centenarian gene in targeting obesity, yet another therapeutic area Genflow appear to be focused, which could have absolutey huge ( excuse the pun) implications and significance for all concerned and greatly increase investor interest and commercial JV partner potential. Looking forward to the next run of newsflow, which i'm sure will drive the sp to new highs in the coming days and weeks. Very exciting times!!! Gl ;-)

20/7/24

Conclusions and future directions

In sum, our results reveal a comprehensive and specific epigenetic and transcriptomic profile in mature adipocytes upon overexpression of a SIRT6 mutant (N308K/A313S), which has a higher prevalence in healthy Ashkenazi centenarians. While the adipogenic process was seemingly unaffected, SIRT6 N308K/A313S overexpression in mature adipocytes led to an ameliorated glucose sensitivity and a deregulation of sympathetic innervation signaling. Our study presents with limitations. The in vitro deacetylase activity (acetyl group) of SIRT6 was shown to be hundreds-fold less potent than its long-chain defatty-acylase activity (malonyl, succinyl, butyryl, myristoyl and palmitoyl groups) on lysine residues [72]. These previously underappreciated histone PTMs are increasingly recognized molecular links between metabolism and epigenetic regulation of gene expression [73]; the role of centSIRT6 enzymatic activity on long-chain fatty acyl lysines remains to be analyzed. A further challenge is understanding how the increased mono-ADP ribosyl-transferase, as in SIRT6 N308K/A313S overexpression in mature adipocytes, may reflect in ameliorated glucose metabolism in the context of obesity [74–76]. A major limitation of our findings is that they are entirely based on an established in vitro model. If confirmed in vivo, for example through the generation of “humanized” mice models carrying N308K/A313S, these finding could highlight the importance of targeting SIRT6 pharmacology with compounds differentially targeting its multiple enzymatic activities to regulate the co-morbidities associated with obesity.

htTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265064/

Funding

This work was supported by GenFlow Bioscience, by the European Commission Horizon 2020 Framework Program (Project 856871—TRANSTEM, to MV) and by grants from the US national Institute of Health, Impetus Grants and Michael Antonov Foundation (to VG). Mass spectrometry was supported by Czech Science Foundation (project No. 22-28190S to GL, PP, ZZ). CIISB, Instruct-CZ Centre of Instruct-ERIC EU consortium, funded by MEYS CR infrastructure project LM2023042, is gratefully acknowledged for the financial support of the measurements at the CEITEC Proteomics Core Facility. Computational resources were provided by the e-INFRA CZ project (ID:90254), supported by MEYS CR.

Latest Sirt6 research, published 20/7/24 with listed authors Vera Gorbunova, Eric Leire and Manlio Vinciguerra .....Gla ;-)

Clin Epigenetics

. 2024 Jul 20

Epigenetic and transcriptional control of adipocyte function by centenarian-associated SIRT6 N308K/A313S mutant

Jan Frohlich # 1 , Niccolò Liorni # 2 , Manuel Mangoni 2 , Gabriela Lochmanová 3 4 , Pavlína Pírek 3 , Nikola Kaštánková 1 , Pille Pata 5 , Jan Kucera 6 7 , George N Chaldakov 8 9 , Anton B Tonchev 8 9 , Illar Pata 5 , Vera Gorbunova 10 , Eric Leire 11 12 , Zbyněk Zdráhal 3 4 , Tommaso Mazza 2 , Manlio Vinciguerra 13 14 15

Abstract

Background: Obesity is a major health burden. Preadipocytes proliferate and differentiate in mature adipocytes in the adipogenic process, which could be a potential therapeutic approach for obesity. Deficiency of SIRT6, a stress-responsive protein deacetylase and mono-ADP ribosyltransferase enzyme, blocks adipogenesis. Mutants of SIRT6 (N308K/A313S) were recently linked to the in the long lifespan Ashkenazi Jews. In this study, we aimed to clarify how these new centenarian-associated SIRT6 genetic variants affect adipogenesis at the transcriptional and epigenetic level.

..........

Conclusions: SIRT6 N308K/A313S overexpression in mature adipocytes ameliorated glucose sensitivity and impacted sympathetic innervation signaling. These findings highlight the importance of targeting SIRT6 enzymatic activities to regulate the co-morbidities associated with obesity.

htTps://pubmed.ncbi.nlm.nih.gov/39033117/

Mechanisms of longevity in the naked mole rat: high molecular weight hyaluronan and stable epigenome.

Seluanov, Andrei

University of Rochester, Rochester, NY, United States

Our aims are: (1) Complete the lifespan study and characterize cancer susceptibility, tissue pathology, genome stability (with Project 3), metabolism, and methylation age (with Project 4) of nmrHAS2 mice. (2) Perform a high throughput screen for hyaluronidase inhibitors and test the effect of these compounds on health, fitness and age- related pathologies in mice. (3) Determine molecular mechanisms responsible for NMR epigenome stability. We will identify specific histone modifying enzymes that are differentially regulated in the NMR, and manipulate them to stabilize the mouse epigenome. We will collaborate with Project 1 to determine the role of SIRT6 in NMR epigenome stability, and with Project 3 to investigate genome and methylome stability in the NMR and mouse cells after epigenetic interventions. The proposed research will identify strategies for exporting the longevity mechanisms found in the naked mole rat to other species.

hTtps://grantome.com/grant/NIH/P01-AG047200-06-5412

No reference to Sirt6 from Vera and co at University of Rochester, but there is in the abstract posted below this article and so fingers crossed this is related to Genflow's following linkedin post, where Vera is also presenting at this coming weeks conference, Gla holders.....Exciting times!!! ;-)

" Exciting news from Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!

Next week, #Genflow will share the company's latest revolutionary #SIRT6 work at the 11th Annual Aging Research & Drug Discovery Meeting"

Scientists discover longevity genes.

Here's how it can extend lifespan of humans

Aug 22, 2024.

For generations, humans have tried to find the elixir which can extend their lives beyond their natural limit and deceive death.

Now, scientists have made a discovery of a gene which has brought humanity very close to this impossible target of achieving longevity.

The gene has been found to possess the capability of promoting cellular repair and reducing the effects of ageing. This discovery has taken the scientific community close to finding methods for extending not just long but healthy lives.

Scientists are now understanding the mechanisms behind this particular longevity gene to find new strategies which can bring significant change in human ageing and lifespan.

The study was carried out by the University of Rochester's team of scientists which comprised Doris Johns Cherry Professor of Biology and Medicine Vera Gorbunova and Professor of Biology Andrei Seluanov.

The Rochester researchers made the dramatic discovery after making a stunning observation of the naked mole rats.

Scientists found that these critters have long lifespans and are able to resist age-related diseases. These rodents are able to survive for nearly 41 years, which is almost a decade longer in comparison to the lives of rodents of their size.

What can this longevity gene do in the human body?

In the experiments carried out by the researchers, this specific gene was transferred into the bodies of mice.

This gene produces high molecular weight hyaluronic acid or HMW-HA which led to significant improvement in the health of the mice and also increased their lifespan by around 4.4 per cent.

HMW-HA is a sort of mechanism which has a stunning effect on ageing and diseases.

HMW-HA is ten times more in the naked mole rats in comparison to the mice and humans. When the scientists removed it from the naked mole rat cells, the cells had more chances of forming tumours.

HMW-HA has the ability to fend off cancer. It was observed that the modified mice were able to protect themselves from spontaneous tumours as well as chemically induced skin cancer.

It was also noted that they suffered less inflammation, which is a sign of ageing, and had a healthier gut.

This discovery has now brought humans to the threshold of improving lifespan and health while reducing inflammation-related diseases in them.

..........

Mechanisms of longevity in t

Exciting stuff Northeast, let's hope we're going to have a run of revolutionary newsflow thereafter. Gl :-)

HTtps://agingpharma.org/

.......

Announcing Longevity Science Foundation as tier 5 sponsor of ARDD 2024

Empowering the future of aging research: Longevity Science Foundation to sponsor ARDD 2024, the world's largest conference on aging research in the biopharmaceutical industry

Business Announcement

Aging Research and Drug Discovery

The University of Copenhagen is excited to announce Longevity Science Foundation as a Tier 5 Sponsor of the 11th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 26 - August 30, 2024 on-site at the Ceremonial Hall, University of Copenhagen, and online.

..........

ARDD 2024 is set to feature a stellar lineup. The Longevity Science Foundation, along with esteemed academic institutions, clinicians, industry leaders, investors, and pharmaceutical companies, will contribute to rich dialogues and present new research in the field of aging. This year, ARDD is proud to be a partner of XPRIZE Healthspan, a 7-year, $101 million global competition to revolutionize the way we approach human aging. Highlighting this collaboration, XPRIZE Healthspan will host its first XPRIZE Healthspan Team Summit at the 11th ARDD. The event underscores a shared commitment between ARDD and XPRIZE to fostering advancements in health and longevity, signaling an important milestone in efforts to enable everyone to live healthier and longer lives through extended healthspan.

“I’m extremely excited about this year's ARDD. We have a stellar academic lineup and an incredibly strong presence from leading companies in the aging field. This year the presence of pharma companies including Lilly, Lundbeck, Novartis, Regeneron and many others have been strengthened and we are super excited that XPRIZE will host their XPRIZE Healthspan Team Summit at ARDD.

htTps://www.eurekalert.org/news-releases/1048285

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,701 followers

5h

🧬 Exciting news from Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!

Next week, #Genflow will share the company's latest revolutionary #SIRT6 work at the 11th Annual Aging Research & Drug Discovery Meeting .

Learn more about #GENF's groundbreaking work: https://loom.ly/MeQymHs

#GENF #GENFF #MASH #longevity #healthspan

Perfectly poised and primed Porter, a very exciting time ahead in the coming days and weeks for some serious UPside!!! In Eric we trust!!! Gla :-)

Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs

Aug 13, 2024

Key Points

Treating aging and its consequences will be a colossal market.

The first seeds of the coming boom have already been planted.

Motley Fool Issues Rare “All In” Buy Alert

Investing based on the segment's long-term prospects is likely to be very lucrative.

I predict that a gold rush in longevity medicines is going to start in the next half-decade or so. That's right: Biotech and pharma companies are going to try developing drugs that can extend human lifespan. And eventually, they're going to succeed, at least somewhat.

The early competitors are already getting down to work. Soon enough, there will surely be great opportunities for investment -- as well as a sea of opportunities to lose your money. Here's a road map for how to invest in the best companies within this new area of medicine, starting with an overview of the playing field as it is today.

Picking up momentum

The second phase is when most investors will start to hear a lot about longevity-promoting medicines in development. Expect biotechs, especially micro caps that are too "out there" to have backing from traditional biopharma venture capital, to be where the majority of the activity occurs.

hTtps://www.fool.com/investing/2024/08/13/the-next-big-biotech-stock-boom-will-be-longevity/

Most certainly Porter, buyers returning in anticipation of news and very few shares now in free float with the majority tightly held for greater things to come. Excitement building!!! Gl :-)